Strateos is a technology company.
Strateos has raised $98.1M across 6 funding rounds.
Strateos has raised $98.1M in total across 6 funding rounds.
Strateos is a technology company that provides a cloud-based automation-as-a-service platform for life science discovery, enabling scientists to remotely design, execute, and analyze experiments using high-throughput robotics and lab control software.[1][2][3] It serves pharmaceutical companies, biotech firms, academic institutions, and government clients by transforming traditional labs into smart data centers that accelerate drug discovery, synthetic biology, cell and gene therapy, and related workflows through AI-enabled data generation and integration.[1][3][4] The platform solves key challenges in reproducibility, efficiency, and data quality by offering on-demand access to remote robotic cloud labs in California, alongside software for controlling private labs, with demonstrated growth through over 27 clients and expansion into AI-driven drug discovery.[3][4]
Strateos originated as Transcriptic, founded in 2012 in Menlo Park, California, pioneering remote access laboratories and lab control software for life sciences.[2][3] The company rebranded to Strateos, with some sources noting a 2019 founding under that name, evolving from early automation efforts into a full platform for data-driven discovery.[1][5] Key figures include Ben Miles, PhD (Head of Product), and Alok Gupta (SVP of Engineering), supporting its development of robotic cloud labs spanning 14,000 sq. ft. in San Diego and Menlo Park with over 100 instruments.[3] A pivotal moment came in December 2023 when Strateos was acquired by Multiply Labs, integrating its experimentation capabilities with robotic pharmaceutical manufacturing to streamline the path from discovery to production.[4]
Strateos rides the wave of lab automation and AI in biotech, capitalizing on trends like high-throughput screening and data-centric drug discovery amid rising R&D costs and demands for speed in pharma and synthetic biology.[1][4] Timing aligns with post-2020 acceleration in remote work and cloud tech adoption, amplified by its 2023 acquisition by Multiply Labs, which bridges discovery-to-manufacturing gaps in a market projected to grow with cell/gene therapies.[4] Market forces favoring it include biotech's need for reproducible data amid talent shortages and regulatory pressures, plus San Diego's biotech hub advantages; it influences the ecosystem by democratizing advanced robotics for smaller firms and academia, fostering interoperability via APIs.[1][3][4]
Post-acquisition, Strateos is poised to expand as a unified discovery-to-production engine within Multiply Labs, targeting integrated platforms for pharma scaling amid AI-biotech convergence.[4] Trends like multimodal data AI and global lab networks will shape its path, potentially evolving influence through Asia partnerships and broader robotic manufacturing adoption.[4] This positions it to redefine life sciences R&D, turning biology into programmable IT as envisioned from its Transcriptic roots.[1]
Strateos has raised $98.1M in total across 6 funding rounds.
Strateos's investors include 8VC, Altaclub VC, ARCH Venture Partners, Bling Capital, Brand New Matter, DCVC (Data Collective), Kima Ventures, LombardStreet Ventures, Lux Capital, MetaProp Ventures, Scott Gottlieb, Picus Capital.
Strateos has raised $98.1M across 6 funding rounds. Most recently, it raised $56.0M Series B in June 2021.